For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
Retatrutide is Eli Lilly's triple GIP/GLP-1/glucagon receptor agonist and the most clinically advanced compound in this series by a wide margin. TRIUMPH-1 Phase 3 results (May 21, 2026) confirmed 28.3% mean weight loss at 80 weeks in 2,339 participants at the 12 mg dose: the highest ever documented in a pharmaceutical obesity trial. 45.3% achieved 30% or more weight loss, a threshold historically associated only with bariatric surgery. 30.3% mean loss at 104 weeks in the extension cohort. TRIUMPH-4 (December 2025) demonstrated 28.7% weight loss plus 75.8% WOMAC pain score reduction in obesity with knee osteoarthritis. FDA submission estimated Q4 2026 to Q1 2027.
Retatrutide represents a fundamental departure from every other compound in this research series. It is a fully synthetic, purpose-engineered pharmaceutical molecule developed by Eli Lilly and Company, not a research peptide. It operates within a fully regulated pharmaceutical development program with large-scale multinational Phase 3 trials. It is not available outside clinical trials as of May 2026.
TRIUMPH-1 pivotal Phase 3 results (announced May 21, 2026): the trial enrolled 2,339 adults with obesity or overweight and at least one weight-related comorbidity without T2D. All three tested doses (4 mg, 9 mg, 12 mg) met primary and key secondary endpoints at 80 weeks. At 12 mg: 28.3% mean weight loss (70.3 lbs) vs 2.2% placebo. At 9 mg: 25.9% (64.4 lbs). At 4 mg: 19.0% (47.2 lbs). 45.3% of 12 mg participants achieved 30% or more weight loss, a threshold historically associated only with bariatric surgery. 65.3% achieved BMI below 30. In a prespecified extension for baseline BMI 35 or above, participants continuing on 12 mg to 104 weeks lost an average of 30.3% (85.0 lbs): the highest ever documented for a pharmaceutical agent. These are topline results; full peer-reviewed publication and FDA submission are pending.
TRIUMPH-4 Phase 3 results (December 11, 2025): in 445 adults with obesity and knee osteoarthritis, retatrutide achieved 28.7% mean weight loss at 68 weeks plus 75.8% reduction in WOMAC pain scores. More than 1 in 8 patients were completely pain-free at 68 weeks.
TRANSCEND-T2D-1 Phase 3 (Q1 2026): positive Phase 3 results in type 2 diabetes confirmed; detailed results pending.
Regulatory timeline: FDA submission estimated Q4 2026 to Q1 2027. Potential approval late 2027 under standard 10-month review. These are analyst projections; Lilly has not confirmed an official submission date. TRIUMPH cardiovascular outcomes, OSA, MASLD, renal, and chronic low back pain trials have not yet reported; results expected throughout 2026 and 2027.
The weight hierarchy among approved and late-stage agents as of May 2026: retatrutide 28.3% (Phase 3, awaiting FDA submission) is above tirzepatide 20.9% (approved) which is above semaglutide 14.9% (approved). No plateau was observed in TRIUMPH-1 through 80 weeks, suggesting continued weight loss potential with longer treatment.
Retatrutide (LY3437943) is a novel triple receptor agonist targeting GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors simultaneously. It was developed by Eli Lilly and Company as the next evolution in incretin-based therapy following the commercial success of semaglutide (GLP-1 monoagonist) and tirzepatide (GLP-1/GIP dual agonist).
The molecule was discovered and disclosed in a 2022 Cell Metabolism paper by Coskun, Urva et al. It has a 6-day plasma half-life engineered for once-weekly subcutaneous dosing, achieved through a C18 fatty acid chain modification enabling albumin binding, consistent with the structural strategy used for semaglutide and tirzepatide.
The TRIUMPH Phase 3 program has enrolled more than 5,800 participants across 13 countries and 8 trials covering obesity, T2D, OSA, osteoarthritis, chronic back pain, cardiovascular outcomes, renal outcomes, and MASLD simultaneously. TRIUMPH-4 (December 2025) was the first Phase 3 readout and met all endpoints. TRIUMPH-1 (May 21, 2026) is the pivotal obesity trial and produced the highest weight loss ever documented in a pharmaceutical Phase 3 trial at 28.3% at 80 weeks. TRANSCEND-T2D-1 (Q1 2026) confirmed positive Phase 3 results in T2D. FDA submission estimated Q4 2026 to Q1 2027.
Retatrutide activates three complementary receptor systems simultaneously through a single continuous helical molecular structure engineered to bind GLP-1, GIP, and glucagon receptors.
GLP-1 receptor activation reduces appetite and food intake via hypothalamic signaling, slows gastric emptying, stimulates glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon, and provides cardiovascular and renal protection consistent with the approved GLP-1R agonist class. This is the mechanism shared with semaglutide.
GIP receptor activation augments GLP-1 effects on appetite, reduces food intake, modulates adipose tissue fat storage, and improves tolerability of GLP-1R agonism. This dual GLP-1/GIP mechanism is shared with tirzepatide. GIP receptor addition appears to improve both efficacy and tolerability compared to GLP-1 monoagonism.
Glucagon receptor activation is what distinguishes retatrutide from all predecessors. The glucagon receptor in the liver drives: increased hepatic fat oxidation (directly reducing steatosis and MASLD), stimulation of thermogenesis and energy expenditure (increasing caloric burn beyond appetite suppression alone), and PCSK9-dependent LDL cholesterol reduction. The glucose-dependent safety of simultaneous GLP-1 and GIP-mediated insulin secretion counterbalances glucagon's hyperglycemic potential, explaining the absence of clinically significant hyperglycemia in trial data.
The absence of a weight-loss plateau in TRIUMPH-1 through 80 weeks may reflect the glucagon receptor component driving sustained metabolic activation: increased energy expenditure that continues to compound weight reduction beyond what appetite suppression alone produces, and beyond what dual agonists typically achieve.
TRIUMPH-1 Phase 3 (n=2,339, 80 weeks, announced May 21, 2026): the pivotal obesity trial. Adults with obesity or overweight and at least one weight-related comorbidity, without T2D. All three doses met primary and key secondary endpoints.
At 12 mg: 28.3% mean weight loss (70.3 lbs) vs 2.2% placebo. 45.3% of participants achieved 30% or more weight loss, a threshold historically associated only with bariatric surgery. 65.3% achieved BMI below 30 at 80 weeks, including 37.5% of those who started with class 3 obesity (BMI 40 or above). In a prespecified extension for baseline BMI 35 or above continuing to 104 weeks: 30.3% mean weight loss (85.0 lbs), the highest ever documented for a pharmaceutical agent at any duration. No weight-loss plateau was observed through 80 weeks.
At 9 mg: 25.9% mean weight loss (64.4 lbs). At 4 mg (single escalation step): 19.0% mean weight loss (47.2 lbs) with a discontinuation rate due to adverse events comparable to placebo, establishing a lower dose with meaningful efficacy and favorable tolerability.
Cardiometabolic secondary endpoints at 12 mg: 24.1 cm waist circumference reduction; favorable changes in non-HDL cholesterol, triglycerides, systolic blood pressure, and hs-CRP. Significant improvements across assessed cardiometabolic health measures confirmed by lead investigator Dr. Ania Jastreboff of Yale.
Phase 2 obesity (NEJM 2023, n=338, 48 weeks): 24.2% mean weight loss at 12 mg vs 2.1% placebo. No plateau observed at 48 weeks, weight still declining at trial end: foreshadowing the greater Phase 3 loss at 80 weeks.
TRIUMPH-4 (n=445, 68 weeks, obesity plus knee osteoarthritis, December 2025): 28.7% mean weight loss at 12 mg. Highest Phase 3 obesity weight loss before TRIUMPH-1.
TRIUMPH-1 is the most consequential single trial result in obesity pharmacotherapy history. 28.3% mean weight loss in 2,339 participants exceeds every prior pharmaceutical benchmark. The 45.3% achieving 30% or more weight loss and 65.3% reaching BMI below 30 establish outcomes that have historically been achievable only through bariatric surgery. The 4 mg dose result (19.0% weight loss, discontinuation comparable to placebo) is clinically important: it establishes a lower-dose option with meaningful efficacy and substantially better tolerability. These are topline results; full peer-reviewed publication is pending. FDA submission is estimated Q4 2026 to Q1 2027 with potential approval in late 2027.
Participants with obesity and knee osteoarthritis taking retatrutide 12 mg lost an average of 28.7% of body weight at 68 weeks. Retatrutide reduced WOMAC pain scores by up to an average of 4.5 points (75.8%) and significantly improved measures of physical function. More than 1 in 8 retatrutide-treated patients were completely free from knee pain at 68 weeks (post-hoc: 14.1% on 9 mg and 12.0% on 12 mg vs 4.2% placebo).
Cardiovascular secondary endpoints: non-HDL cholesterol reduced, triglycerides reduced, hsCRP reduced, systolic blood pressure reduced by 14.0 mmHg at highest dose. No new safety signals. Adverse events consistent with incretin class.
TRIUMPH-4 was the first Phase 3 readout for retatrutide and met all primary and key secondary endpoints. The combination of 28.7% weight loss and 75.8% WOMAC pain reduction, with more than 1 in 8 patients becoming completely pain-free, demonstrates that sufficient weight reduction directly translates to structural and symptomatic joint benefit at a scale not previously achieved pharmacologically. Knee osteoarthritis is one of the most prevalent disabling conditions globally, representing a major unmet need where current pharmacotherapy is limited to analgesics and joint replacement.
Phase 2 T2D (Lancet 2023, n=281, 36 weeks): HbA1c improved by 2.2%, with 77 to 82% of participants achieving euglycemia (HbA1c 6.5% or below). 57 to 63% achieved 15% or more weight loss: the highest weight loss figures reported in a T2D medication trial at that point. LDL cholesterol reduction of approximately 20% via glucagon receptor-mediated PCSK9 degradation added a cardiovascular protective dimension. Superior efficacy to dulaglutide 1.5 mg on both HbA1c and weight.
TRANSCEND-T2D-1 Phase 3 (Q1 2026): positive results confirmed in T2D; detailed trial data pending formal presentation and publication.
The Phase 2 T2D data is without precedent in diabetology: achieving euglycemia in 77 to 82% of patients within 36 weeks while simultaneously producing greater than 16% weight loss and approximately 20% LDL reduction is a composite metabolic effect no prior pharmacological agent has matched. The TRANSCEND-T2D-1 Phase 3 positive topline confirms Phase 2 translation to scale. Detailed Phase 3 T2D data will be presented at a future medical meeting.
Mean relative change from baseline in liver fat at 24 weeks: -42.9% (1 mg), -57.0% (4 mg), -81.4% (8 mg), -82.4% (12 mg), and +0.3% placebo (all p less than 0.001 vs placebo).
At 12 mg, more than 90% of participants with obesity and MASLD achieved normalization of liver fat at 48 weeks: the greatest liver fat reduction ever documented pharmacologically. The glucagon receptor's direct hepatic fat oxidation effect is the mechanistic basis for this result, distinct from the indirect hepatic effects of GLP-1 and GIP agonism.
A dedicated Phase 3 MASLD trial is underway within the TRIUMPH program. Given MASLD's prevalence (estimated 30% of global population), a positive Phase 3 MASLD result would represent a major additional regulatory milestone.
82% relative liver fat reduction at 48 weeks with more than 90% normalization at the highest dose dwarfs what any approved or late-stage investigational MASLD treatment has achieved, including resmetirom (FDA-approved March 2024) and semaglutide's ESSENCE trial. The glucagon receptor mechanism driving hepatic fat oxidation is a direct pharmacological effect distinct from weight-loss-mediated indirect hepatic benefits. Phase 3 MASLD data is the most important pending TRIUMPH readout after the cardiovascular outcomes trial.
Phase 3 OSA trials are ongoing within the TRIUMPH program. Primary endpoint is change in Apnea-Hypopnea Index (AHI). The mechanistic rationale is direct: pharyngeal fat deposition is a primary anatomical driver of OSA severity. At 28.3% mean weight loss in TRIUMPH-1, the degree of upper airway fat reduction achievable with retatrutide substantially exceeds what semaglutide (14.9%) achieves, which was sufficient for FDA OSA approval in December 2024.
If OSA benefit scales proportionally with weight loss, retatrutide's greater magnitude should produce substantially greater AHI reduction than semaglutide's SURMOUNT-OSA results (approximately 25 to 29 events/hour reduction).
No OSA-specific results yet. The weight-loss magnitude from TRIUMPH-1 (28.3%) substantially exceeds semaglutide's approved OSA dose weight loss (approximately 15%), creating strong prior expectations. Results pending 2026.
TRIUMPH-4 Phase 3 cardiovascular secondary endpoints: non-HDL cholesterol reduced, triglycerides reduced, hsCRP significantly reduced (reflecting anti-inflammatory effects), systolic blood pressure reduced by 14.0 mmHg at highest dose. LDL reduction of approximately 20% in Phase 2 T2D trial via PCSK9 mechanism.
The dedicated cardiovascular outcomes trial is underway. The question is whether retatrutide demonstrates cardiovascular event reduction comparable to or exceeding semaglutide's SELECT trial result (HR 0.80 in non-diabetic obesity) and tirzepatide's SURPASS-CVOT result (noninferior to dulaglutide in T2D). If retatrutide produces a superior CV outcomes result, it would substantially strengthen the regulatory case for broad approval.
Secondary cardiovascular endpoint data from TRIUMPH-4 confirms consistent risk marker improvement across lipids, blood pressure, and inflammation. The dedicated CV outcomes trial is the highest-stakes remaining TRIUMPH readout. A positive result equivalent to or exceeding SELECT would be the definitive regulatory catalyst for broad approval across multiple indications. Results expected 2026 to 2027.
Chronic low back pain Phase 3: mechanistic rationale parallels osteoarthritis. Obesity is a major driver of both mechanical spinal load and systemic inflammation contributing to disc degeneration and nerve sensitization. The 75.8% WOMAC pain reduction in TRIUMPH-4 provides a strong prior for analogous low back pain benefit. No trial results yet.
Renal outcomes Phase 3: GLP-1 receptor agonists have demonstrated nephroprotection beyond weight loss as established in the FLOW trial with semaglutide (24% composite kidney endpoint reduction, NEJM 2024). No retatrutide-specific renal efficacy data has been published. The class precedent and the magnitude of weight loss achievable with retatrutide both support a positive prior expectation.
Both applications are Phase 3 ongoing with no results yet. The OA pain precedent from TRIUMPH-4 is a credible prior for chronic low back pain. The semaglutide FLOW precedent is a credible prior for renal outcomes. Results expected 2026 to 2027.
Retatrutide is not available outside clinical trials as of May 2026. This is a pharmaceutical drug in active Phase 3 development, not a research peptide. FDA submission estimated Q4 2026 to Q1 2027 based on analyst projections; Lilly has not confirmed an official submission date. ClinicalTrials.gov lists active TRIUMPH trial enrollment sites for those seeking clinical trial access. Research-grade purchasing is not applicable.
Retatrutide vs semaglutide: TRIUMPH-1 (28.3%, 80 weeks) vs STEP-1 (14.9%, 68 weeks). Retatrutide produces approximately 90% greater relative weight loss. The glucagon receptor addition is the mechanistic basis: GLP-1 only cannot produce this magnitude.
Retatrutide vs tirzepatide: TRIUMPH-1 (28.3%, 80 weeks) vs SURMOUNT-1 (20.9%, 72 weeks). Retatrutide's triple mechanism produces approximately 35% greater relative weight loss than tirzepatide's dual mechanism. SURMOUNT-5 established tirzepatide's superiority over semaglutide; TRIUMPH-1 now extends the ceiling further.
Retatrutide vs survodutide (both GLP-1 plus glucagon): survodutide SYNCHRONIZE-1 (16.6%, 76 weeks) vs retatrutide TRIUMPH-1 (28.3%, 80 weeks). The addition of GIP to the GLP-1 plus glucagon combination produces dramatically greater weight loss. GIP receptor agonism appears to substantially amplify the weight loss achievable from GLP-1 plus glucagon alone.
Retatrutide's safety profile is consistent across Phase 1, Phase 2, and Phase 3 data and is class-consistent with GLP-1 receptor agonists.
Gastrointestinal effects are the primary adverse event category: nausea, diarrhea, and constipation, occurring predominantly during dose escalation. TRIUMPH-1 topline reported GI adverse events consistent with the incretin class, with discontinuation rates of 4.1% (4 mg), 6.9% (9 mg), and 11.3% (12 mg) vs 4.9% placebo: dose-dependent but the 4 mg discontinuation rate was comparable to placebo. Slow dose titration starting at 2 mg substantially reduces GI adverse event burden.
The theoretical concern for glucagon receptor agonism causing hyperglycemia has not materialized clinically: glucose-dependent counterregulation by GLP-1 and GIP receptor activation maintains euglycemia.
TRIUMPH-4 cardiovascular secondary endpoints: non-HDL cholesterol reduced, triglycerides reduced, hsCRP reduced, systolic blood pressure reduced by 14.0 mmHg at highest dose. No new safety signals emerged.
Longer-term cardiovascular and renal safety characterization will come from the ongoing TRIUMPH outcomes trials. As a not-yet-approved investigational drug, retatrutide does not have regulatory labeling; its safety profile will be formally characterized through the NDA review process.
TRIUMPH-1, announced May 21, 2026, is the most consequential single trial result in obesity pharmacotherapy history. 28.3% mean weight loss in 2,339 participants at 80 weeks, 45.3% achieving 30% or more weight loss, 65.3% achieving BMI below 30, and 30.3% at 104 weeks in the extension: these figures establish retatrutide as categorically beyond what any approved pharmaceutical has achieved in obesity.
The central remaining questions are no longer about efficacy. They are: whether the cardiovascular outcomes trial will match or exceed semaglutide's SELECT result (HR 0.80), whether the benefit-risk profile at doses producing maximal efficacy will be acceptable to regulators given the dose-dependent GI adverse event profile, and whether FDA submission and review will proceed on the estimated Q4 2026 to Q1 2027 timeline.
The weight loss hierarchy as of May 2026 is now confirmed: retatrutide 28.3% (Phase 3, awaiting submission) is above tirzepatide 20.9% (approved) which is above semaglutide 14.9% (approved). No approved pharmaceutical approaches 30% weight loss. Retatrutide does at 104 weeks.
Retatrutide serves as the benchmark for this entire research series: what validated, properly funded, Phase 3-tested peptide pharmacology looks like at maturity. Every other compound in this series is measured against this standard.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use